Comprehensive Medical Weight Loss Denver
Get the latest developments in medical weight loss at Clinical Nutrition Center in Denver, Colorado, a doctor-supervised weight loss center. Ethan Lazarus, MD is a medical weight loss doctor helping patients achieve long-term weight control.
Dr. Ethan Lazarus, MD, DABOM, DABFM, MFOMA | Clinical Nutrition Center | October 5, 2026 Novo Nordisk announced at EASD in Milan on October 1 that 23 of 26 participants with obesity and elevated liver fat reached normal liver fat…
Your body doesn’t announce every change with fanfare. Menopause is different. Along with the hot flashes and sleep disruption, there’s a quieter shift happening in your fat tissue — one that doesn’t show up on a standard scale but has…
CagriSema: Novo Nordisk’s New Weight Loss Drug Hit 22.7% — Here’s What That Means for Colorado Patients Novo Nordisk’s stock dropped 9% the day the CagriSema results landed. Investors were hoping for 25%. They got 22.7%. Let that sink in:…
A patient came in last month with a fatty liver diagnosis and an A1C of 6.2%. She was not surprised. Her father had the same thing. Her sister had the same thing. She figured it was genetic and inevitable. She…
Sleep deprivation adds 385 calories a day to your intake — not because you lack willpower, but because your hormones are working against you. Here's what the science says.
Teenagers With Obesity Aren’t Waiting for the Operating Room Anymore A study published in JAMA Pediatrics on July 20, 2026, by Messiah and colleagues has a number that should make every pediatrician in Colorado pause. GLP-1 receptor agonist use among…
For years, patients asked about a pill version of GLP-1 medication. “Anything I can swallow instead of inject?” The answer used to be: not really. Oral semaglutide existed, but the fine print made it impractical for most people. That changed…
Good news for Colorado state employees: GLP-1 medications for weight loss are a covered benefit again. Effective May 1, 2026, the State of Colorado reinstated GLP-1 coverage for obesity treatment under its employee health plan — covering approximately 30,000 state…
Stopping vs. Switching — They’re Not the Same Thing Before anything else: there’s an important distinction between stopping a GLP-1 and switching from one GLP-1 to another. Patients often conflate them — and the distinction matters enormously for your plan.…
Let me start with a number that should get your attention: 28.7%. That’s how much body weight participants lost in the latest Phase 3 trial of retatrutide, Eli Lilly’s investigational triple-agonist obesity medication. At 68 weeks, the average weight loss…
